Despite success in hematologic malignancies, the treatment landscape of chimeric antigen
receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18. 2 (CLDN18. 2) …

2509 Background: As a promising approach for some cancers, chimeric antigen receptor T
cell therapy has limited success in solid tumors. Claudin18. 2 (CLDN 18.2) is a stomach …

Abstract Background Claudin18. 2 (CLDN18. 2), a gastric-specific membrane protein, has
been regarded as a potential therapeutic target for gastric cancer and other cancer types …

Background T cells engineered to express chimeric antigen receptors (CARs) have
established efficacy in the treatment of B-cell malignancies, but their relevance in solid …

Pancreatic cancer lacks effective therapy. Here, we reported two metastatic pancreatic
cancer patients administrated with Claudin 18.2 (CLDN 18.2) CART therapy after the failure …

Abstract Claudin 18.2 (CLDN18. 2) is a tight-junction protein. CLDN18. 2-targeting strategy
has cut a striking figure in CLDN18. 2 positive patients with advanced gastric cancer …

Chimeric antigen receptor (CAR)–T cells have shown efficacy in patients with B cell
malignancies. Yet, their application for solid tumors has challenges that include limited …

Gastric cancer (GC) is one of the most commonly diagnosed malignancies and,
unfortunately, still has a high mortality rate. Recent research points to CAR-T …

Genetic redirection of T lymphocytes with chimeric antigen receptors (CARs) has soared
from treating cancers preclinically to FDA approval for hematologic malignancies and …

The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid
tumors, and could be a promising treatment target. We report dose escalation results from …